Interobserver Variability in HER‐2 Immunostaining Interpretation of Metastatic HER2 Low Breast Cancers in Cytology Specimens

Abstract

BackgroundApproximately, 55% of breast carcinomas are reported to be HER‐2 low breast carcinomas. Trastuzumab‐Deruxtecan is a new FDA‐approved targeted therapy for HER‐2 low metastatic breast carcinomas, making it essential that all efforts are made to identify these tumors in specimens submitted for pathologic examination. Cytology specimens are often the first and only modality of this assessment due to the ease of specimen procurement. This study aimed to determine the variability in HER‐2 immunostaining interpretation among observers using cytologic specimens from metastatic sites.DesignA pathology database search was made to identify metastatic breast carcinoma reported in cytology specimens. A manual search was then done to identify cases of HER‐2 low category, H&E cell block and HER‐2 neu immunostain slides were retrieved for a total of 50 cases. Reviewer #1 and #2 independently interpreted HER‐2 immunostain of all 50 cases. Only discordant cases were sent for reviewer‐3 interpretation. All three were blinded by the metastatic site, and original HER‐2 interpretation.ResultsOf 50 cases, 11 cases (22%) were reported as concordant scores between reviewer #1 and reviewer #2 but had a discordant original IHC report. Additionally, 4 cases (8%) had discordant reporting of HER2 IHC stain between reviewer #1 and reviewer #2 making a total of 15 cases (30%) with overall discordant results.ConclusionThis study highlights the interobserver variability of HER‐2 immunostain interpretation for HER‐2 low category of breast carcinomas. We recommend the need for more robust laboratory techniques including molecular for uniform identification of these unique targetable metastatic breast carcinoma groups.